Osteoimmunology: A View from the Bone

Advances in Immunology

Volumn 95, Issue , 2007, Pages 149-165

  David, Jean Pierre ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; BONE; BONE DEVELOPMENT; BONE MARROW CELL; CELL TYPE; DEREGULATION; HOMEOSTASIS AND REGULATION; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MULTIPLE MYELOMA; NONHUMAN; ORGANOGENESIS; OSSIFICATION; OSTEOCLAST; OSTEOIMMUNOLOGY; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; B-LYMPHOCYTES; BONE AND BONES; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; INTERFERONS; OSTEOCLASTS; OSTEOGENESIS; TUMOR NECROSIS FACTORS;

EID: 34548494841     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(07)95005-1     Document Type: Review

References (85)

1. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J. Clin. Invest. 107 (2001) 1375-1385
2. Abu-Amer Y., Erdmann J., Alexopoulou L., Kollias G., Ross F.P., and Teitelbaum S.L. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J. Biol. Chem. 275 (2000) 27307-27310
3. Adams G.B., Martin R.P., Alley I.R., Chabner K.T., Cohen K.S., Calvi L.M., Kronenberg H.M., and Scadden D.T. Therapeutic targeting of a stem cell niche. Nat. Biotechnol. 25 (2007) 238-243
4. Aggarwal B.B. Signalling pathways of the TNF superfamily: A double-edged sword. Nat. Rev. Immunol. 3 (2003) 745-756
5. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., and Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319 (1986) 516-518
6. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., and Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
7. Caamano J.H., Rizzo C.A., Durham S.K., Barton D.S., Raventos-Suarez C., Snapper C.M., and Bravo R. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J. Exp. Med. 187 (1998) 185-196
8. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
9. Chung J.Y., Park Y.C., Ye H., and Wu H. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115 (2002) 679-688
10. Corral D.A., Amling M., Priemel M., Loyer E., Fuchs S., Ducy P., Baron R., and Karsenty G. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. USA 95 (1998) 13835-13840
11. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., and Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115 (2002) 4317-4325
12. David J.P., Mehic D., Bakiri L., Schilling A.F., Mandic V., Priemel M., Idarraga M.H., Reschke M.O., Hoffmann O., Amling M., and Wagner E.F. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest. 115 (2005) 664-672
13. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., Korb A., Smolen J., Hoffmann M., Scheinecker C., van der Heide D., Landewe R., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13 (2007) 156-163
14. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R., Armstrong A., Shen V., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13 (1999) 2412-2424
15. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006) 836-848
16. Engsig M.T., Chen Q.J., Vu T.H., Pedersen A.C., Therkidsen B., Lund L.R., Henriksen K., Lenhard T., Foged N.T., Werb Z., and Delaisse J.M. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151 (2000) 879-889
17. Fox S.W., and Chambers T.J. Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem. Biophys. Res. Commun. 276 (2000) 868-872
18. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., Leonardi A., Tran T., Boyce B.F., and Siebenlist U. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
19. Gao Y., Grassi F., Ryan M.R., Terauchi M., Page K., Yang X., Weitzmann M.N., and Pacifici R. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 117 (2007) 122-132
20. Gelb B.D., Shi G.P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996) 1236-1238
21. Giuliani N., Rizzoli V., and Roodman G.D. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 108 (2006) 3992-3996
22. Goldring S.R. Inflammatory mediators as essential elements in bone remodeling. Calcif. Tissue Int. 73 (2003) 97-100
23. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., and Wagner E.F. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266 (1994) 443-448
24. Hayashi T., Kaneda T., Toyama Y., Kumegawa M., and Hakeda Y. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs in IFN-beta-inhibited osteoclast formation. J. Biol. Chem. 277 (2002) 27880-27886
25. Heavey B., Charalambous C., Cobaleda C., and Busslinger M. Myeloid lineage switch of Pax5 mutant but not wild-type B cell progenitors by C/EBPalpha and GATA factors. EMBO J. 22 (2003) 3887-3897
26. Heider U., Hofbauer L.C., Zavrski I., Kaiser M., Jakob C., and Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem. Biophys. Res. Commun. 338 (2005) 687-693
27. Horowitz M.C., Xi Y., Pflugh D.L., Hesslein D.G., Schatz D.G., Lorenzo J.A., and Bothwell A.L. Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. J. Immunol. 173 (2004) 6583-6591
28. Horowitz M.C., Bothwell A.L., Hesslein D.G., Pflugh D.L., and Schatz D.G. B cells and osteoblast and osteoclast development. Immunol. Rev. 208 (2005) 141-153
29. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., and Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265 (1999) 144-150
30. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 (1997) 1285-1289
31. Jochum W., David J.P., Elliott C., Wutz A., Plenk Jr. H., Matsuo K., and Wagner E.F. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6 (2000) 980-984
32. Johnson R.S., Spiegelman B.M., and Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71 (1992) 577-586
33. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440 (2006) 692-696
34. Kaji K., Katogi R., Azuma Y., Naito A., Inoue J.I., and Kudo A. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J. Bone Miner. Res. 16 (2001) 1593-1599
35. Kanazawa K., and Kudo A. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J. Bone Miner. Res. 20 (2005) 840-847
36. Kanazawa K., Azuma Y., Nakano H., and Kudo A. TRAF5 functions in both R. J. Bone Miner. Res. 18 (2003) 443-450
37. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
38. Kawaguchi H., Manabe N., Miyaura C., Chikuda H., Nakamura K., and Kuro-o M. Independent impairment of osteoblast and osteoclast differentiation in Klotho mouse exhibiting low-turnover osteopenia. J. Clin. Invest. 104 (1999) 229-237
39. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., and Kollias G. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10 (1991) 4025-4031
40. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 (2000) 275-286
41. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., Tesio M., Samstein R.M., Goichberg P., Spiegel A., Elson A., and Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12 (2006) 657-664
42. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
43. Kotake S., Nanke Y., Mogi M., Kawamoto M., Furuya T., Yago T., Kobashigawa T., Togari A., and Kamatani N. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur. J. Immunol. 35 (2005) 3353-3363
44. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997) 45-51
45. Laiosa C.V., Stadtfeld M., and Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu. Rev. Immunol. 24 (2006) 705-738
46. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
47. Lee S.K., and Lorenzo J. Cytokines regulating osteoclast formation and function. Curr. Opin. Rheumatol. 18 (2006) 411-418
48. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104 (2001) 487-501
49. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., van der Heide A., Itie A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13 (1999) 1015-1024
50. Loser K., Mehling A., Loeser S., Apelt J., Kuhn A., Grabbe S., Schwarz T., Penninger J.M., and Beissert S. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12 (2006) 1372-1379
51. Manabe N., Kawaguchi H., Chikuda H., Miyaura C., Inada M., Nagai R., Nabeshima Y., Nakamura K., Sinclair A.M., Scheuermann R.H., and Kuro-o M. Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol. 167 (2001) 2625-2631
52. Miyamoto T., Ohneda O., Arai F., Iwamoto K., Okada S., Takagi K., Anderson D.M., and Suda T. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98 (2001) 2544-2554
53. Moser K., Tokoyoda K., Radbruch A., MacLennan I., and Manz R.A. Stromal niches, plasma cell differentiation and survival. Curr. Opin. Immunol. 18 (2006) 265-270
54. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., Nakao K., Nakamura K., Katsuki M., Yamamoto T., and Inoue J. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4 (1999) 353-362
55. Nilsson S.K., Johnston H.M., Whitty G.A., Williams B., Webb R.J., Denhardt D.T., Bertoncello I., Bendall L.J., Simmons P.J., and Haylock D.N. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106 (2005) 1232-1239
56. Nutt S.L., Heavey B., Rolink A.G., and Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401 (1999) 556-562
57. Okada S., Wang Z.Q., Grigoriadis A.E., Wagner E.F., and von Rüden T. Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. Mol. Cell. Biol. 14 (1994) 382-390
58. Owens J.M., Gallagher A.C., and Chambers T.J. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J. Immunol. 157 (1996) 936-940
59. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., Ponomaryov T., Taichman R.S., Renzana-Seisdedos F., Fujii N., Sandbank J., Zipori D., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3 (2002) 687-694
60. Ponomaryov T., Peled A., Petit I., Taichman R.S., Habler L., Sandbank J., Renzana-Seisdedos F., Magerus A., Caruz A., Fujii N., Nagler A., Lahav M., et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J. Clin. Invest. 106 (2000) 1331-1339
61. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46 (2002) 785-792
62. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F., and Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110 (2002) 1419-1427
63. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111 (2003) 821-831
64. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., Tanaka S., Kodama T., Akira S., Iwakura Y., Cua D.J., and Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 (2006) 2673-2682
65. Schett G., Redlich K., Hayer S., Zwerina J., Bolon B., Dunstan C., Gortz B., Schulz A., Bergmeister H., Kollias G., Steiner G., and Smolen J.S. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48 (2003) 2042-2051
66. Sha W.C., Liou H.C., Tuomanen E.I., and Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80 (1995) 321-330
67. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
68. Stier S., Ko Y., Forkert R., Lutz C., Neuhaus T., Grunewald E., Cheng T., Dombkowski D., Calvi L.M., Rittling S.R., and Scadden D.T. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J. Exp. Med. 201 (2005) 1781-1791
69. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K., Nakamura K., and Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 (2000) 600-605
70. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889-901
71. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., Yokochi T., Oda H., Nakamura K., Ida N., Wagner E.F., and Taniguchi T. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416 (2002) 744-749
72. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
73. Urbanek P., Wang Z.Q., Fetka I., Wagner E.F., and Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79 (1994) 901-912
74. Visnjic D., Kalajzic Z., Rowe D.W., Katavic V., Lorenzo J., and Aguila H.L. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103 (2004) 3258-3264
75. Walsh N.C., and Gravallese E.M. Bone loss in inflammatory arthritis: Mechanisms and treatment strategies. Curr. Opin. Rheumatol. 16 (2004) 419-427
76. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., and Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 360 (1992) 741-745
77. Wei S., Wang M.W., Teitelbaum S.L., and Ross F.P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277 (2002) 6622-6630
78. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., and Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4 (1999) 1041-1049
79. Xie H., Ye M., Feng R., and Graf T. Stepwise reprogramming of ns into macrophages. Cell 117 (2004) 663-676
80. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
81. Yin T., and Li L. The stem cell niches in bone. J. Clin. Invest. 116 (2006) 1195-1201
82. Zenz R., Eferl R., Kenner L., Florin L., Hummerich L., Mehic D., Scheuch H., Angel P., Tschachler E., and Wagner E.F. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
83. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., and bu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276 (2001) 563-568
84. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., Ross J., Haug J., Johnson T., Feng J.Q., Harris S., Wiedemann L.M., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
85. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., Dunstan C., Kollias G., Steiner G., Smolen J., and Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50 (2004) 277-290